176 related articles for article (PubMed ID: 30881494)
1. Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Yuan T; Zhang F; Zhou X; Li Y; Zhang Y; Xu Y; Wang X
Oncol Lett; 2019 Apr; 17(4):3719-3726. PubMed ID: 30881494
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.
Wang HQ; Liu BQ; Gao YY; Meng X; Guan Y; Zhang HY; Du ZX
Br J Pharmacol; 2009 Nov; 158(5):1405-12. PubMed ID: 19681889
[TBL] [Abstract][Full Text] [Related]
3. [Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines].
Zhang TC; Chu HJ; Zhao JQ; Zhou XY; Shi DR
Zhonghua Xue Ye Xue Za Zhi; 2010 Oct; 31(10):671-4. PubMed ID: 21223717
[TBL] [Abstract][Full Text] [Related]
4. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells].
Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139
[TBL] [Abstract][Full Text] [Related]
5. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
6. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
7. Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Jia X; Wen Z; Sun Q; Zhao X; Yang H; Shi X; Xin T
J BUON; 2019; 24(5):1985-1991. PubMed ID: 31786865
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
9. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
[TBL] [Abstract][Full Text] [Related]
10. Impact of MAPK and PI3K/AKT signaling pathways on Malabaricone-A induced cytotoxicity in U937, a histiocytic lymphoma cell line.
Manna A; De Sarkar S; De S; Bauri AK; Chattopadhyay S; Chatterjee M
Int Immunopharmacol; 2016 Oct; 39():34-40. PubMed ID: 27398613
[TBL] [Abstract][Full Text] [Related]
11. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
12. Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling.
Yang H; Zhang P; Li J; Gao Y; Zhao L; Li J; Guo M; Zhang J; Li H; Wang F; Yuan Y
Onco Targets Ther; 2020; 13():8593-8600. PubMed ID: 32904547
[TBL] [Abstract][Full Text] [Related]
13. microRNA-340 induces apoptosis by downregulation of BAG3 in ovarian cancer SKOV3 cells.
Qu F; Wang X
Pharmazie; 2017 Aug; 72(8):482-486. PubMed ID: 29441908
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Lv X; Feng L; Ge X; Lu K; Wang X
J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
17. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
18. PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Prasad SB; Yadav SS; Das M; Modi A; Kumari S; Pandey LK; Singh S; Pradhan S; Narayan G
Cell Oncol (Dordr); 2015 Jun; 38(3):215-25. PubMed ID: 25821107
[TBL] [Abstract][Full Text] [Related]
19. Combination of cecropinXJ and LY294002 induces synergistic cytotoxicity, and apoptosis in human gastric cancer cells via inhibition of the PI3K/Akt signaling pathway.
Xia LJ; Wu YL; Zhang FC
Oncol Lett; 2017 Dec; 14(6):7522-7528. PubMed ID: 29344198
[TBL] [Abstract][Full Text] [Related]
20. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
